CA2923664C - Compositions and methods for the delivery of molecules into live cells - Google Patents
Compositions and methods for the delivery of molecules into live cells Download PDFInfo
- Publication number
- CA2923664C CA2923664C CA2923664A CA2923664A CA2923664C CA 2923664 C CA2923664 C CA 2923664C CA 2923664 A CA2923664 A CA 2923664A CA 2923664 A CA2923664 A CA 2923664A CA 2923664 C CA2923664 C CA 2923664C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cell
- cells
- dtat
- cpp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876006P | 2013-09-10 | 2013-09-10 | |
| US61/876,006 | 2013-09-10 | ||
| PCT/US2014/055021 WO2015038662A1 (en) | 2013-09-10 | 2014-09-10 | Compositions and methods for the delivery of molecules into live cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2923664A1 CA2923664A1 (en) | 2015-03-19 |
| CA2923664C true CA2923664C (en) | 2023-05-02 |
Family
ID=52666235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2923664A Active CA2923664C (en) | 2013-09-10 | 2014-09-10 | Compositions and methods for the delivery of molecules into live cells |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9662404B2 (https=) |
| EP (1) | EP3043811B1 (https=) |
| JP (1) | JP6659546B2 (https=) |
| AU (1) | AU2014318839B2 (https=) |
| CA (1) | CA2923664C (https=) |
| ES (1) | ES2794599T3 (https=) |
| WO (1) | WO2015038662A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2981716C (en) | 2015-04-10 | 2022-04-12 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
| FR3048698B1 (fr) | 2016-03-11 | 2021-03-05 | Univ Claude Bernard Lyon | Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 |
| CN110291100B (zh) * | 2016-10-12 | 2024-06-11 | 费尔丹生物公司 | 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒 |
| US11629170B2 (en) | 2016-10-12 | 2023-04-18 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| EP3604520A4 (en) * | 2017-03-22 | 2020-12-16 | Kyoto University | PEPTIDE FOR CYTOSOLIC ADMINISTRATION |
| US11821003B2 (en) | 2017-08-14 | 2023-11-21 | Sanford Burnham Prebys Medical Discovery Institute | Cardiogenic mesoderm formation regulators |
| WO2020091535A1 (ko) * | 2018-11-02 | 2020-05-07 | 순천향대학교 산학협력단 | 점막 투과 촉진용 펩타이드 및 이를 포함하는 조성물 |
| JP2022512977A (ja) | 2018-11-08 | 2022-02-07 | サメイション バイオ， インコーポレイテッド | ミニヌクレオソームコアタンパク質及び核酸送達における使用 |
| KR102201154B1 (ko) * | 2019-03-26 | 2021-01-12 | 가천대학교 산학협력단 | 폴리글루타메이트-TAT-Cre 융합 단백질의 제조방법 |
| CA3040645A1 (en) | 2019-04-18 | 2020-10-18 | Feldan Bio Inc. | Peptide-based non-proteinaceous cargo delivery |
| AU2021254697A1 (en) | 2020-04-13 | 2022-11-10 | Summation Bio Inc. | Modified mini-nucleosome core proteins and use in nucleic acid delivery |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258774B1 (en) * | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| EP2224940A1 (en) * | 2007-11-30 | 2010-09-08 | Cytomatrix PTY LTD | Methods of inducing pluripotency involving oct4 protein |
| WO2010059806A2 (en) * | 2008-11-20 | 2010-05-27 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells without the use of viral vectors |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US20120128655A1 (en) * | 2009-04-03 | 2012-05-24 | The Mclean Hospital Corporation | Induced pluripotent stem cells |
| EP4321168A3 (en) * | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| WO2012090150A2 (en) | 2010-12-27 | 2012-07-05 | Compugen Ltd | New cell-penetrating peptides and uses thereof |
-
2014
- 2014-09-10 ES ES14843936T patent/ES2794599T3/es active Active
- 2014-09-10 WO PCT/US2014/055021 patent/WO2015038662A1/en not_active Ceased
- 2014-09-10 JP JP2016540943A patent/JP6659546B2/ja active Active
- 2014-09-10 US US14/482,946 patent/US9662404B2/en active Active
- 2014-09-10 AU AU2014318839A patent/AU2014318839B2/en active Active
- 2014-09-10 EP EP14843936.7A patent/EP3043811B1/en active Active
- 2014-09-10 CA CA2923664A patent/CA2923664C/en active Active
-
2017
- 2017-05-23 US US15/602,967 patent/US20170258933A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016530303A (ja) | 2016-09-29 |
| US20150099690A1 (en) | 2015-04-09 |
| CA2923664A1 (en) | 2015-03-19 |
| WO2015038662A1 (en) | 2015-03-19 |
| US20170258933A1 (en) | 2017-09-14 |
| ES2794599T3 (es) | 2020-11-18 |
| US9662404B2 (en) | 2017-05-30 |
| EP3043811A4 (en) | 2017-09-20 |
| JP6659546B2 (ja) | 2020-03-04 |
| AU2014318839B2 (en) | 2019-12-05 |
| EP3043811B1 (en) | 2020-03-25 |
| EP3043811A1 (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2923664C (en) | Compositions and methods for the delivery of molecules into live cells | |
| AU2014318839A1 (en) | Compositions and methods for the delivery of molecules into live cells | |
| EP1991560B1 (en) | Peptide having cell membrane penetrating activity | |
| Lundin et al. | Distinct uptake routes of cell-penetrating peptide conjugates | |
| Takayama et al. | Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas) | |
| KR102201430B1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
| JP6517692B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
| US20180208912A1 (en) | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate | |
| Mäger et al. | Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay | |
| US20110182920A2 (en) | Identification of a novel cysteine-rich cell penetrating peptide | |
| Noguchi et al. | Mechanism of PDX-1 protein transduction | |
| US20150369740A1 (en) | Optogenetic probes for measuring membrane potential | |
| Buyanova et al. | Discovery of a cyclic cell-penetrating peptide with improved endosomal escape and cytosolic delivery efficiency | |
| WO2016035918A1 (ko) | 신규한 융합체 및 이의 제조 방법 | |
| KR101695792B1 (ko) | 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도 | |
| JPWO2016052442A1 (ja) | 細胞質送達ペプチド | |
| Kawaguchi et al. | An approach for the intracellular delivery of IgG via enzymatic ligation with a cell-permeable attenuated cationic amphiphilic lytic peptide | |
| Doh | Validation of heterodimeric TAT-NLS peptide as a gene delivery enhancer | |
| KR20090122769A (ko) | 세포내로 단백질을 전달하는 방법 및 이를 위한 펩타이드 | |
| Najjar et al. | An L-to D-amino acid conversion in the cell penetrating peptide dfTAT influences proteolytic stability, endocytic uptake, and endosomal escape | |
| Joseph | Poly (Arginine) Derived Cancer-Targeting Peptides for the Development of a Cancer-Targeted Gene Therapy Approach in HepG2 Liver Cancer Cells | |
| WO2005087795A1 (es) | Péptidos como portadores penetrantes de células | |
| Mahon Jr | Thiazole orange peptidoconjugates as nucleic acid and cellular probes | |
| Erazo | Cytosolic Delivery of Proteins, Peptides and Cell-Impermeable Small Molecules Into Live Cells Utilizing Virus-Inspired Multivalent Cell-Penetrating Peptides: Principles and Mechanisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190905 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251006 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |